[논문]The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients

Koshino, Yoshifumi; Bahk, Won-Myong; Sakai, Hideaki; Kobayashi, Takayuki

doi:10.2147/NDT.S48158

The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients 원문보기

Neuropsychiatric disease and treatment, v.9, 2013년, pp.1273 - 1280

Koshino, Yoshifumi (Iris Medical Clinic, Kanazawa University, Ishikawa, Japan) , Bahk, Won-Myong (Yeouido St Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea) , Sakai, Hideaki (Meguro Station East Mental Clinic, Shinagawa, Tokyo, Japan) , Kobayashi, Takayuki (Medicines Development (Neurosciences), Development and Medical Affairs, GlaxoSmithKline, Shibuya, Tokyo, Japan)

Abstract ▼ AI-Helper

This study was conducted to compare the efficacy and safety of bupropion sustained-release (SR) formulation orally administered at daily doses of 150 mg/day (once daily) and 300 mg/day (150 mg twice daily) for 8 weeks versus placebo in Asian patients with major depressive disorder. The mean change from baseline in Montgomery–Åsberg Depression Rating Scale (MADRS) total score at week 8 was compared between each of the bupropion SR dose groups and the placebo group using an analysis of covariance with the multiplicity adjustment by Dunnett’s step-down procedure. A total of 569 subjects met all of the inclusion criteria and proceeded to the treatment phase. The subjects proceeding to the treatment phase included 454 Japanese patients and 115 Korean patients. There was no statistically significant difference between each of the bupropion SR dose groups and the placebo group in the primary efficacy endpoint of change from baseline in MADRS total score at week 8. Similar results were generally obtained for all of the secondary efficacy endpoints. The secondary analysis and the other subgroup analysis did not show a statistically significant difference in efficacy. There was no substantial difference in the type, severity, and incidence of adverse events (AEs) between the bupropion SR dose groups and the placebo group, which indicates a favorable safety profile for bupropion SR. There were no significant findings in subjects treated with bupropion SR in regard to sexual dysfunction, weight change, and withdrawal syndrome, which are frequently recognized as clinical concerns associated with selective serotonin reuptake inhibitors, widely used for the treatment of depression.

주제어

참고문헌 (22)

1 Fava M Rush AJ Thase ME 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL Prim Care Companion J Clin Psychiatry 2005 7 106 113 16027765

상세보기
2 Cipriani A Furukawa TA Salanti G Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis Lancet 2009 373 9665 746 758 19185342
3 Coleman CC King BR Bolden-Watson C A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine Clin Ther 2001 23 1040 1058 11519769

상세보기
4 Jefferson JW Rush AJ Nelson JC Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reducing energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study J Clin Psychiatry 2006 67 865 873 16848645
5 Montgomery SA Åsberg M A new depression rating scale designed to be sensitive to change Br J Psychiatry 1979 134 382 389 444788
6 American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th ed Text revision Washington, DC American Psychiatric Association 2000
7 Mundt JC Greist JH Jefferson JW Is it easier to find what you are looking for if you think you know what it looks like? J Clin Psychopharmacol 2007 27 121 125 17414233

상세보기
8 Mundt JC Snyder PJ Cannizzaro MS Chappie K Geralts DS Voice acoustic measures of depression severity and treatment response collected via interactive voice response (IVR) technology J Neurolinguistics 2007 20 50 64 21253440
9 Kobak KA Reynolds WM Rosenfeld R Greist JH Development and validation of a computer-administered version of the Hamilton Depression Rating Scale Psychol Assess 1990 2 56 63
10 Kunigi H Koga N Hashikura M Validation of computer-administered clinical rating scale: Hamilton Depression Rating Scale assessment with Interactive Voice Response technology – Japanese version Psychiatry Clin Neurosci 2013 67 253 258 23683156
11 Hamilton M A rating scale for depression J Neurol Neurosurg Psychiatry 1960 23 56 62 14399272

상세보기
12 Rash AJ Gullion CM Basco MR Jarrett RB Trivedi MH The Inventory of Depressive Symptomatology (IDS): psychometric properties Psychol Med 1996 26 477 486 8733206

상세보기
13 Rush AJ Carmody T Reimitz PE The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and Self-Report (IDS-SR) ratings of depressive symptoms Int J Methods Psychiatr Res 2000 9 45 59

상세보기
14 International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH Harmonized Tripartite Guideline: guideline for good clinical practice J Postgrad Med 2001 47 199 203 11832625
15 Posternak MA Zimmerman M Keitner GI Miller IW A reevaluation of the exclusion criteria used in antidepressant efficacy trials Am J Psychiatry 2002 159 191 200 11823258
16 Pae CU Lim HK Han C Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion Expert Rev Neurother 2007 7 1251 1263 17939764
17 Lieberman JA Greenhouse J Hamer RM Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy Neuropsychopharmacology 2005 30 445 460 15647752

상세보기
18 Thase ME Haight BR Richard N Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials J Clin Psychiatry 2005 66 974 981 16086611

상세보기
19 Clayton AH Pradko JF Croft HA Prevalence of sexual dysfunction among newer antidepressants J Clin Psychiatry 2002 63 357 366 12000211

상세보기
20 Serretti A Mandelli L Antidepressants and body weight: a comprehensive review and meta-analysis J Clin Psychiatry 2010 71 1259 1272 21062615

상세보기
21 Haddad PM Antidepressant discontinuation syndromes Drug Saf 2001 24 3 183 197 11347722

상세보기
22 Columbia University Medical Center Columbia-Suicide Severity Rating Scale (C-SSRS) [homepage on the internet] Available from: http://www.cssrs.columbia.edu/ . Accessed July 31, 2013

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (22)

이 논문을 인용한 문헌

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트